There "simply will" be demand for Covid variants from now into the foreseeable future... Sars-cov-2 has shown to have about 6 months between major mutations in the first year alone... the first in italy /continental Europe, the next a pair of quasi-convergent mutations in South Africa and UK. As hosts increase and time goes on, expect to see more mutation events, some divergence, and higher transmission, viral load, and mortality in the most critical LLMab market: severe / critical.

But the largest Covid-19 market for LLMab will continue to be long haulers, a much larger portion of the Covid-19 population, and one that will only grow with time.

Quote:

---

there simply won't be a demand for $2B of LL past 21 or 22.

Read More: https://investorshangout.com/post/view?id=602...z6kZM3vUOZ

---